Merck KGaA is taking a fourth option in its deal with bispecific immunotherapy biotech F-Star Therapeutics, which has attracted the eyes of a who’s who of Big Pharma. The German pharma has already picked up three candidates from the F-Star collaboration, beginning in May 2019, then again in July 2020 and most recently in March 2021. Merck obviously likes what it sees in F-Star, which also counts Johnson & Johnson, AstraZeneca Bristol Myers Squibb and AbbVie as partners. Source: Fierce Biotech 5/1/22